𝔖 Bobbio Scriptorium
✦   LIBER   ✦

An open trial of paroxetine for the “offensive subtype” of taijin kyofusho and social anxiety disorder

✍ Scribed by Toshihiko Nagata; Irene van Vliet; Hisashi Yamada; Kouhei Kataoka; Toshiya Iketani; Nobuo Kiriike

Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
123 KB
Volume
23
Category
Article
ISSN
1091-4269

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Therapeutic advances: Paroxetine for the
Therapeutic advances: Paroxetine for the treatment of social anxiety disorder
✍ R. Bruce Lydiard; Julio Bobes 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB 👁 2 views

## Data from early studies of selective serotonin reuptake inhibitors have shown that these agents are effective in the treatment of social anxiety disorder (social phobia). This review highlights the outcomes of three large clinical trials of paroxetine in patients with social anxiety disorder. In

How long should a trial of escitalopram
How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database
✍ David S. Baldwin; Dan J. Stein; Ornah T. Dolberg; Borwin Bandelow 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB 👁 2 views

## Abstract ## Objective To extend the knowledge of course of improvement in patients with major depressive disorder (MDD), social anxiety disorder (SAD) or generalised anxiety disorder (GAD) participating in randomised placebo‐controlled trials (RCTs) and to infer the optimal duration of initial

An open, non-randomised comparison of es
An open, non-randomised comparison of escitalopram and duloxetine for the treatment of subjects with Generalized Anxiety Disorder
✍ Andrea Pierò; Enrica Locati 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB 👁 1 views

## Abstract ## Objectives This study compares the effectiveness of a 6‐months treatment with escitalopram (ESC), a selective serotonin reuptake inhibitor, or duloxetine (DUL), a balanced serotonin and nor‐adrenaline reuptake inhibitor, in 43 subjects with Generalized Anxiety Disorder (GAD). ## Me

Effectiveness and tolerability of paroxe
Effectiveness and tolerability of paroxetine controlled release (CR) in the treatment of major depressive disorder: an open-label, prospective, multi-center trial in Korea
✍ Chi-Un Pae; Won-Myong Bahk; Duk-In Jon; Sang-Yeol Lee; Bo-Hyun Yoon; Kyung Joon 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB 👁 2 views

## Abstract ## Objectives This study evaluated the effectiveness and tolerability of paroxetine controlled release (CR) for the treatment of Korean patients with major depressive disorder (MDD) in a naturalistic treatment setting. ## Methods One hundred and ninety patients with MDD were enrolled